May 28, 2024Clarametyx Biosciences Appoints Renowned Experts to Augment Strategic and Scientific Advisory BoardsRead More April 22, 2024Clarametyx Biosciences Expands Team Expertise to Accelerate Pipeline MomentumRead More January 5, 2024Clarametyx Biosciences Announces $33 Million Series A Financing to Advance Anti-Biofilm Biologics for Serious Bacterial InfectionsRead More June 1, 2023Clarametyx Announces Positive Early Phase 1 Safety Findings on CMTX-101, Immune-Enabling Antibody TherapyRead More May 30, 2023Clarametyx Biosciences Announces Changes to Its Scientific Advisory BoardRead More November 30, 2022Clarametyx Initiates Phase 1 Study of Immune-Enabling Antibody Therapy CMTX-101 Against Community-Acquired Bacterial PneumoniaRead More October 5, 2022Clarametyx Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase 1 Study of Immune-Enabling Antibody Therapy CMTX-101Read More April 4, 2022CARB-X Awards Clarametyx Biosciences $3.89 Million in Additional Option Funding to Accelerate Anti-biofilm Technology for Life-threatening Bacterial InfectionsRead More December 20, 2021Clarametyx Biosciences Awarded $3.15 Million Grant From NIH to Advance a Broad-spectrum Vaccine Technology for Bacterial InfectionsRead More